Elad Sharon and Colleagues: How a Common Trait Unfairly Excludes Black Patients from Cancer Trials
Elad Sharon, Associated Professor of Medicine at Dana-Farber, shared a post on X:
“Very proud of this effort led by one of our former Dana-Farber fellows, Lauren Merz, on the Duffy null phenotype. Thanks to JAMA Oncology for highlighting! Important to see that many otherwise healthy patients are unfairly being excluded because of an arbitrary number… the National Cancer Institute”
Quoting JAMA Oncology’s post:
“Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.”
Title: Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility
Authors: Lauren E. Merz, Yating Wang, Angel Cronin, Elad Sharon, Thomas P. Walsh, Stephen P. Hibbs, Christopher S. Lathan, Andrew Hantel
Read full article here.
Never miss hematology updates with Hemostasis Today.
-
Jul 5, 2026, 21:06Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
-
Jul 5, 2026, 21:06Priyanka Kumari: IV Fluids and Isotonic Solution
-
Jul 5, 2026, 21:05Ahmed Rizq: Would You Thrombolyse a Stable Patient?
-
Jul 5, 2026, 21:03Emmanuel Obeng Ofori: Diagnosing Anaemia – Why Treating the Root Cause Matters More Than Simply Raising the Haemoglobin
-
Jul 5, 2026, 21:02Mohit Koladia: The Pharmacist’s Role in Stroke Prevention for Atrial Fibrillation
-
Jul 5, 2026, 20:22J. Meireles-Brandao: Exploring the Approach to Thrombophillias
-
Jul 5, 2026, 20:13Kavya Keerthana: The Platelet Count Everyone Calls ‘Reactive’ Until It Isn’t
-
Jul 5, 2026, 20:00Paul Kariuki: Why Altruism Isn’t Enough to Save Kenya’s Blood System
-
Jul 5, 2026, 19:53Tareq Abadl: Post-Transfusion Reactions – Can You Identify the Cause?